Humira - (40mg/0.8mL; Injection)

Generic Name	Adalimumab	Innovator	Abbvie
Dosage	40mg/0.8mL; Injection	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	Less Than 5
Indication	HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****			*******	******** ** ********	******** ** *** **, ****
********** *********			*******	******** ** *******	** **** *, ****
******			*******	******** ** *******	** **** **, ****

Chronology Of Events